Novel expression cassettes for increasing apolipoprotein AI transgene expression in vascular endothelial cells

doi:10.21203/rs.3.rs-1594337/v1

Download PDF

Article

Novel expression cassettes for increasing apolipoprotein AI transgene expression in vascular endothelial cells

https://doi.org/10.21203/rs.3.rs-1594337/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Transduction of endothelial cells (EC) with a vector that expresses apolipoprotein A-I (APOAI) reduces atherosclerosis in arteries of fat-fed rabbits. However, the effects on atherosclerosis are partial and might be enhanced if APOAI expression could be increased. We tested 4 strategies—primarily in vitro—to increase APOAI expression from our current highest-expressing vector: addition of 2 types of enhancers, addition of computationally identified EC-specific cis-regulatory modules (CRM), and insertion of the rabbit APOAI gene at the transcription start site (TSS) of genomic sequences cloned from genes that are highly expressed in cultured EC. Addition of a shear stress-responsive enhancer did not increase APOAI expression. Addition of 2 copies of a Mef2c enhancer increased APOAI expression from a moderately active promoter/enhancer, but decreased APOAI expression from our most highly active promoter/enhancer. Of 11 computationally identified CRM, 3 increased APOAI expression from the moderately active promoter (2–7-fold; P < 0.05); none increased expression from the highly active promoter/enhancer. Insertion of the APOAI gene into the TSS of highly expressed EC genes did not increase expression above levels obtained with moderately active promoter/enhancer. High performance of our current highest-expressing vector was confirmed; new strategies are needed to further increase APOAI transgene expression in EC.

Vascular endothelial cells (EC) have several important physiological roles including modulation of vascular tone and permeability, control of hemostasis, and regulation of leukocyte trafficking during inflammatory reactions.(1) EC are easily accessible via intravenous or intraarterial injection of gene-transfer vectors and therefore have been targets for gene-therapy approaches that aim to treat both local and systemic diseases.(2–4) EC are particularly attractive targets for gene therapy that prevents or treats atherosclerosis because they regulate entry of both inflammatory cells and cholesterol (major components of atherosclerotic lesions) into the blood vessel wall.(5, 6)

Effective gene therapy, delivered to EC, requires expression cassettes that achieve high-level transgene expression.(7) Expression cassettes that yield high levels of transgene expression increase the likelihood that gene therapy will be effective, while simultaneously allowing use of lower vector doses that minimize vector-related toxicity.(8, 9) Other groups attempted to increase transgene expression in EC by constructing expression cassettes that contain EC-specific promoters and enhancers.(10–18) However, expression from these EC-specific cassettes was reliably lower than expression levels achieved with non-cell-type-specific promoters such as the cytomegalovirus (CMV) immediate early and phosphoglycerate kinase promoters.(12, 14, 16) Accordingly, we used the CMV promoter to test whether expression of a therapeutic apolipoprotein A-I (APOAI) transgene in EC could prevent and reverse atherosclerosis in rabbits.(19, 20) This therapy reduced—but did not eliminate—atherosclerosis, suggesting a need for a more highly expressing APOAI cassette.

Several years ago, we constructed an EC-specific expression cassette containing a modified mouse endothelin-1 (Edn1) enhancer-promoter (termed 4XETE) and a posttranslational regulatory element (together termed the “4XETE-oPRE” cassette).(21) This cassette expressed an interleukin-10 transgene at levels at least as high as the CMV promoter in EC both in vitro and in vivo.(22) We then tested whether the 4XETE-oPRE cassette could express APOAI at similarly high levels. Remarkably, in vitro expression of APOAI from the 4XETE-oPRE cassette exceeded levels achieved with the CMV promoter; however, in vivo expression from the 4XETE-oPRE cassette was initially lower than from the CMV cassette.(23)

To further increase APOAI expression above levels achieved with the CMV or the 4XETE-oPRE cassettes in vivo, we tested several strategies including codon optimization of the APOAI transgene, complete removal of the 3´ untranslated region of APOAI, and co-expression of interleukin-10 with APOAI. However, none of these strategies increased APOAI expression.(23) Here we tested several new strategies aimed at increasing APOAI expression above levels achieved with the 4XETE-oPRE cassette: addition of enhancer sequences reported to be active in EC; addition of endothelial-specific cis-regulatory modules (CRM; effective in increasing transgene expression in other cell types);(24–26) and insertion of the APOAI gene at the transcription start site of genomic sequences cloned from 4 genes that are highly expressed in cultured EC.

Construction of expression cassettes and helper-dependent adenovirus (HDAd)

We previously reported construction of the plasmid pBshuttle-4XETE-gApoAI-oPRE and the corresponding HDAd vector HDAd-4XETE-gApoAI-oPRE.(22) Both constructs contain the rabbit APOAI gene driven by a modified murine Edn1 promoter (termed 4XETE; includes the Edn1 promoter and 3 added tandem repeats of the Edn1 enhancer) along with the optimized posttranscriptional regulatory element (oPRE) of the woodchuck hepatitis virus(21) (Supplementary Fig. S1). We noted that the Edn1 promoter contains a 5´-GAGACC-3´ sequence in the “noncoding” DNA strand. This sequence, reported to be a shear stress response element (SSRE), was originally identified in the platelet-derived growth factor B chain promoter(27) and was shown to function in vascular endothelial cells, when placed in the coding strand, upstream of synthetic promoters.(28) To enable testing of an SSRE in the coding strand, we first mutated the endogenous 5´-GAGACC-3´ sequence in the noncoding strand (QuikChange Lightning Site-Directed Mutagenesis Kit; Agilent Technologies, Santa Clara, CA) to 5´-ATGTCA-3´, yielding pBshuttle-4XETE-gApoAI-oPRE-mSSRE (Supplementary Figure S1). As described in Results, this plasmid was not useful, and all remaining plasmids were constructed with the noncoding 5´-GAGACC-3´ sequence intact.

We used site-directed mutagenesis to insert the 5´-GAGACC-3´ sequence into the coding strand of pBshuttle-4XETE-gApoAI-oPRE, just upstream of the 4XETE sequence. The new plasmid was named pBshuttle-SSRE-4XETE-gApoAI-oPRE (Supplementary Fig. S1). Homologous recombination was used, as described,(22) to transfer the SSRE-4XETE-gApoAI-oPRE sequence from pBshuttle-SSRE-4XETE-gApoAI-oPRE to the HDAd backbone plasmid pC4HSU (Microbix Biosystems, Toronto, Ontario, Canada).(29) The resulting plasmid was used, along with 293Cre4 cells and H14 helper virus,(30) to generate HDAd-SSRE-4XETE-gApoAI-oPRE. Concentrated HDAd vector preparations, characterized as described,(22, 31) were 1.4 to 2.8 10¹² viral particles/mL with helper virus contamination <1% and E1A-containing genomes <1 in 10⁶ viral genomes.

To construct additional expression cassettes in which DNA sequences were tested for their ability to increase APOAI expression above levels obtained with the 4XETE-gApoAI-oPRE cassette, we first used site-directed mutagenesis to insert MluI and BglII restriction sites upstream of the 4XETE sequence in pBShuttle-4XETE-gApoAI-oPRE, generating pBShuttle-MB-4XETE-gApoAI-oPRE (Supplementary Fig. S1). We then constructed an oligomer containing a 44-bp murine Mef2c enhancer,(32) flanked by MluI and BglII restriction sites on one end and a BamHI restriction site (Integrated DNA Technologies, Coralville, IA) on the other end. We ligated 1 copy of this oligomer into MluI-BglII-digested pBShuttle-MB-4XETE-gApoAI-oPRE, generating pBshuttle-1XMEF2C-4XETE-gApoAI-oPRE (Supplementary Fig. S1). We used the controlled and ordered oligonucleotide ligation procedure(33) to generate pBshuttle-2XMEF2C-4XETE-gApoAI-oPRE (Supplementary Fig. S1), as well as pBshuttle-3XMEF2C-4XETE-gApoAI-oPRE, pBshuttle-4XMEF2C-4XETE-gApoAI-oPRE, and pBshuttle-5XMEF2C-4XETE-gApoAI-oPRE (not shown).

To construct expression cassettes in which putative DNA enhancer sequences were tested for their ability to increase APOAI expression from a cassette containing only 1 copy of the Edn1 enhancer (i.e., 1XETE-gApoAI-oPRE; Supplementary Fig. S1), we used site-directed mutagenesis to remove the 3 added copies of the Edn1 enhancer (total 160 bp) from pBshuttle-MB-4XETE-gApoAI-oPRE, leaving the MluI and BglII sites intact. The product of this reaction, pBshuttle-MB-1XETE-gApoAI-oPRE (Supplementary Fig. S1) was used, along with the Mef2c oligomers mentioned above and the controlled and ordered oligonucleotide ligation procedure, to generate pBshuttle-1XMEF2C-1XETE-gApoAI-oPRE, pBshuttle-2XMEF2C-1XETE-gApoAI-oPRE, etc. (Supplementary Fig. S1; 3X 4X and 5XMEF2C constructs are not shown). We also used site-directed mutagenesis to delete the MluI and BglII restriction sites from pBshuttle-MB-1XETE-gApoAI-oPRE, generating a control plasmid, pBshuttle-1XETE-gApoAI-oPRE (Supplementary Fig. S1).

We used a similar approach to construct expression cassettes in which single copies of endothelial cell (EC) cis-regulatory modules (CRM; identified as described below) were inserted upstream of the 4XETE and 1XETE sequences in pBshuttle-MB-4XETE-gApoAI-oPRE and pBshuttle-MB-1XETE-gApoAI-oPRE. Essentially, we used PCR and human DNA from 293 Cre cells(30) as a template to generate amplicons containing each of 11 CRM (all with introduced 5´ MluI sites and 3´ BglII sites), we digested the amplicons with MluI and BglII, and ligated the products into the MluI/BglII-digested plasmids. These expression cassettes were termed CRM(1–11)-1XETE-gApoAI-oPRE and CRM(1–11)-4XETE-gApoAI-oPRE (Supplementary Fig. S1).

We also constructed 4 expression cassettes in which APOAI expression was driven by large (2 035 – 8 880 bp) genomic segments of each of 4 genes that are highly and relatively specifically expressed in EC: VWF, THBS1, EFEMP1, and CDH5. To identify these 4 genes, we began by using publicly available search engines and PubMed, along with search terms that included “endothelium genes,” “endothelium-specific genes,” and “endothelial cell specific.” These searches identified 30 candidate genes (Supplemental Table 1). We consulted the relevant publications and confirmed that each publication reported expression of these genes in EC. We then consulted the Gene Expression Atlas (http://www.ebi.ac.uk/gxa/home), which includes quantitative transcription data generated from the ENCODE project.(34) For each of the 30 genes, we interrogated ENCODE-derived data in the Gene Expression Atlas using: endothelial cell-derived cell line, the gene name, ENCODE – long polyA RNA, and whole cell. The output of this interrogation yielded a table that reports relative expression levels of the 30 genes in 18 cell lines, including cultured human umbilical vein EC (HUVEC; Supplementary Table S1). EFEMP1 and THBS1 were by far the most highly expressed genes in HUVEC and had relatively EC-specific expression. VWF and CDH5 were the next most highly expressed genes in HUVEC and were expressed only in HUVEC.

To determine which genomic sequences to incorporate in the 4 expression cassettes, we consulted papers that identified cis-acting positive regulators of transcription located near the promoters of the 4 genes.(12, 35-44) We were also careful to include the genomic regions in which the CRM were located (see below). Into these genomic sequences, we ligated a cassette that contains elements of the rabbit APOAI gene (beginning with the start codon, and including all 3 coding exons, both introns, and 51 bp of 3´ untranslated region), as well as the oPRE and SV40 polyadenylation signal. This APOAI cassette was inserted at the translational start sites of each of these 4 genomic sequences (Supplementary Fig. S2). The VWF genomic sequence extends from 843 bp upstream of the transcription start site to the translation start site, including the promoter, first exon, and first intron (total 2 322 bp). We used 2 segments of the EFEMP1 gene, with one segment placed upstream and one segment downstream of the APOAI gene. The upstream sequence extends from 243 base pairs upstream of the EFEMP1 transcription start site to immediately upstream of the EFEMP1 start codon, including the promoter, first exon, first intron, and part of the second exon (total 1 942 bp). The 3´ segment begins immediately downstream of the EFEMP1 start codon, extends for 5 676 base pairs downstream of the EFEMP1 translation start site (including the 2nd, 3rd, and 4th exons, the 2nd and 3rd introns, and part of the 4th intron). We used 2 separate segments of the EFEMP1 gene because CRM were identified both 5´ and 3´ of the EFEMP1 translation start site, and because leaving exon 2 (containing the EFEMP1 transcription start site) intact would potentially result in transcription and translation of a chimeric mRNA that included both EFEMP1 and APOAI sequences. The THBS1 genomic sequence extends from 1 270 bp upstream of the transcription start site to the translation start site, including the promoter, first exon, first intron, and part of the second exon (total 2 035 bp). The CDH5 genomic sequence includes 2 segments. The first segment extends from 6 721 bp upstream of the transcription start site through part of the first intron (total 8 821 bp). The second segment includes a sequence from the 3´ end of the first intron, including the splice acceptor site, and part of the second exon (total 59 bp). A plasmid containing the second segment for CDH5 and part of the 3´ end of the first segment was constructed by Integrated DNA Technologies.

We cloned these genomic regions by PCR amplification (Q5 High-Fidelity DNA Polymerase, New England Biolabs, Ipswich, MA) of human genomic DNA (Promega, Madison, WI) or of the human CDH5 gene-containing plasmid constructed by Integrated DNA Technologies. Primers were designed based on the human GRCh38/hg38 genome assembly. We constructed plasmids containing the VWF, EFEMP1, and CDH5 genomic sequences by ligation of PCR-amplified human genomic DNA to the rabbit APOAI gene and pBshuttle, using Gibson Assembly kits (New England Biolabs; Quantabio, Beverly, MA; GenScript, Piscataway, NJ). pBshuttle-THBS1-gApoAI-oPRE was constructed by GenScript. Plasmid identities were confirmed by restriction digestion (all plasmids) and by sequencing either across all of the Gibson Assembly junctions or across the entire insert (pBshuttle-THBS1-gApoAI-oPRE).

Identification of cis-regulatory modules (CRM)

To identify potential EC-specific CRM, we updated a computational approach that was used to identify liver-, cardiac-, and skeletal muscle-specific CRM.(24-26) As described above, we identified 4 target genes that are expressed highly and relatively specifically in EC (VWF, EFEMP1, CDH5, and THBS1). In the original approach to CRM identification, transcription factors were linked to target genes using transcription factor binding site (TFBS) predictions based on libraries of positional weight matrices; however, this approach is known to result in numerous false positives.(45)

Here we updated this approach to incorporate information contained in the ReMap 2015 ChIP-Seq database of 237 experimentally validated TFBS (http://tagc.univ-mrs.fr/remap/). This database, created by Griffon et al,(46) uses systematic integration of public non-ENCODE and ENCODE experimental data(47) to construct matrices that link TFBS to target genes, relying on the concept of regulatory potential (i.e., the likelihood that a gene is regulated by a transcription factor). Tang et al(48) modeled the influence of each TFBS on gene regulation as a function that decreases monotonically with increasing distance from the transcription start site of the gene. We used these tools to calculate—for each of the 237 transcription factors contained in the ReMap 2015 ChIP-Seq data sets—a regulatory potential on each of the 25 635 genes annotated in the human hg19 genome assembly. From the distribution of regulatory potential scores for every transcription factor, a p-value was calculated from the fraction of regulatory potential scores exceeding a given value. From these data, we constructed a general regulatory potential transcription factor – target gene matrix, in which genes are in rows and transcription factors are in columns. For every gene/transcription factor cell, the number 1 indicates if the gene is potentially regulated by the transcription factor at the specified p-value cutoff, the number 0 if it is not. For every specified p-value cutoff, a different general transcription factor – target gene matrix is constructed that can be used directly in the distance difference matrix approach, replacing the original positional weight matrices predictions-based transcription factor – target gene matrices.

We used the set of 4 genes that are expressed highly and relatively specifically in EC (VWF, EFEMP1, CDH5, and THBS1) and 1 000 background sets of 8 randomly selected genes as input for the distance difference matrix method.(49) Because the background sets are generated randomly, we avoided sampling or selection bias by repeating the experiment 7 times. To identify transcription factors that are consistently found among the top regulatory factors in replicate experiments, we used a rank-product meta-analysis algorithm.(50) This yielded 8 top-regulatory transcription factors using a q-value cutoff of 0.05 (AR, E2F7, ESR2, ETS1, GATA3, PRDM1, SNAPC1, and TAF7). Clusters of TFBS associated with these factors were then used to identify putative CRM in the vicinity of the loci of the highly expressed, EC-specific genes.

In view of the limited number of target genes, putative CRM were identified visually with the UCSC Genome Browser and the GRCh37/hg19 assembly. For this purpose, a custom browser guiding track containing the binding regions for the 8 top regulators was generated and uploaded. We used additional tracks to help identify putative CRM including the layered HUVEC H3K4Me1 track (regulatory elements), the layered HUVEC H3K4Me3 track (promoters), the layered HUVEC H3K27Ac track (active regulatory elements), the DNase I Hypersensitivity tracks (open chromatin; regulatory regions and promoters), and the Vertebrate Multiz Alignment & Conservation (100 species) track (sequences maintained by natural selection). Using these tools, we identified putative CRM consisting of clusters of top-regulatory TFBS and coinciding with the strongest epigenetic modifications favoring transcription in HUVEC, indicators of open chromatin regions, and highly conserved sequence elements. This approach identified 11 potential EC-specific CRM (Supplementary Table S2). The source code is available at https://github.ugent.be/pdbleser/Tfdiff_REMAP.

Testing expression cassettes in vitro

Bovine aortic EC (BAEC; Cell Applications Inc., San Diego, CA) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin and were used at passages 5-8. Human aortic endothelial cells from a single donor, 37-year-old female, (HAEC; Lonza, Walkersville, MD) were grown in EBM-2 Basal Medium supplemented with EGM-2 SingleQuots Supplements (Lonza) and used at passages 4-7. Pooled Human Umbilical Vein Endothelial Cells (HUVEC; Lonza, Walkersville, MD), were grown in EGM-2 Basal Medium supplemented with EGM-2 SingleQuots Supplements (Lonza) and used at passages 1-6.

To test the mSSRE-containing expression cassette, BAEC were grown in 35-mm dishes to 80% confluence and transfected with plasmid DNA. These and all other transfections were done with jetPRIME transfection reagent (Polyplus, New York, NY), using the manufacturer’s protocol. Six hours after transfection, the cells were washed with DMEM and their medium was replaced. Fifty-one hours after transfection, the cells were harvested for RNA and DNA quantitation. To test the expression cassette containing an exogenous SSRE, BAEC were grown to 80% confluence in 6-well plates and transfected with plasmid DNA. Five hours after transfection, the cells were washed with DMEM and their medium was replaced. Twenty-four hours after transfection, the cells were harvested for RNA and DNA quantitation. In all cases, cells were harvested and lysed either by the addition of Buffer RLT Plus (Qiagen) + 2-mercaptoethanol (for RNA and/or DNA quantitation), the addition of Buffer RLT (Qiagen) + 2-mercaptoethanol (for RNA quantitation), or the addition of TRI Reagent (Zymo Research, Irvine, CA).

To test expression cassettes containing Mef2c oligomers, CRM, or genomic constructs, BAEC were grown to 80% confluence and transfected in 6-well plates. Five hours after transfection, the cells were washed twice with DMEM and 600 µL of DMEM was added to the wells. Twenty-four hours after transfection, the conditioned medium was removed, and the cells harvested for RNA and DNA quantitation. The CRM-containing expression cassettes and the genomic constructs were also transfected into HAEC and HUVEC, in 12-well plates. Four hours after transfection, the cells were washed with PBS, and 1 mL of fresh medium was added to the wells. Twenty-four hours after transfection, the cells were harvested for RNA and DNA quantitation.

We purified EC RNA and DNA with the AllPrep DNA/RNA Mini Kit (Qiagen, Germantown, MD). Alternatively, RNA and DNA were purified separately with the Direct-zol RNA Miniprep Kit (Zymo Research) and the DNeasy Blood and Tissue Kit (Qiagen). RNA was digested with DNase I (Thermo Fisher Scientific, Waltham, MA) to remove contaminating genomic DNA; RNA samples from HAEC and HUVEC were digested with both DNase I (New England Biolabs) and PvuII (New England Biolabs) to remove contaminating genomic DNA. Use of PvuII was required to ensure digestion of human APOAI genomic DNA. RNA was reverse-transcribed and amplified with the Luna Universal Probe One-Step RT-qPCR Kit (New England Biolabs). Alternatively, RNA was reverse-transcribed with the qScript Flex cDNA Kit (Quantabio) and the APOAI cDNA was measured by quantitative real-time PCR amplification using PerfeCTa FastMix II (Quantabio). APOAI mRNA levels were normalized to GAPDH mRNA levels, measured in cells from the same well. Normalized APOAI expression levels were further normalized for transfection efficiency, assessed by measuring plasmid DNA in extracts of cells in the same well (for BAEC) or of cells in a separate well transfected in parallel (for HAEC). Primers and probes for qPCR (Supplementary Table S3) were ordered from Integrated DNA Technologies. When Ct values for GAPDH or plasmid DNA suggested a failed PCR or failed transfection in a well, results from that well were omitted. These criteria, which resulted in exclusion of results from a small number of wells, were applied uniformly to all plasmids.

In vivo gene transfer to rabbit carotid arteries

Rabbits were fed a standard laboratory diet (16% rabbit PLT, Albers Animal Feed, Bellevue, WA). After 1 week of acclimation to the animal facility, 16 male New Zealand White rabbits (3.0–3.5 kg, Western Oregon Rabbit Co., Philomath, OR) underwent surgical isolation of both common carotid arteries, followed by temporary occlusion, and local luminal infusion of either HDAd-SSRE-4XETE-gApoAI-oPRE or HDAd-4XETE-gApoAI-oPRE (each at 2 10¹¹ viral particles/mL diluted in DMEM) as previously described.(51) Carotid arteries were harvested either 3 or 28 days after gene transfer. Three spaced segments (proximal, mid, and distal) of each transduced artery were snap-frozen in liquid nitrogen for RNA analysis. Total RNA was extracted from these segments (RNeasy Mini Kit, Qiagen) and was quantified by Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE). APOAI mRNA was measured by quantitative reverse transcriptase-mediated PCR.(52)

Statistics

For comparing two groups, we used Student’s t-test if conditions of normality and equal variance were met. If not, we used a Mann-Whitney rank-sum test. For experiments that compared multiple groups (i.e., number of Mef2c enhancer copies, different CRM, or the 4 genomic knock-in constructs), we used the Kruskal-Wallis one-way ANOVA on ranks with Dunn’s method for post-hoc corrections for multiple comparisons.

Addition of a shear stress response element (SSRE) does not increase APOAI expression

To test the activity of an exogenous SSRE placed upstream of our highest-expressing APOAI cassette (4XETE-gApoAI-oPRE; Supplementary Fig. S1), we first mutated an endogenous SSRE sequence (5´-GAGACC-3´)(28) that we identified in the “noncoding” strand of the murine Edn1 promoter (the Edn1 promoter is included in the 4XETE sequence). Mutation of this sequence to 5´-ATGTCA-3´ (in the 4XETE-gApoAI-oPRE-mSSRE vector; Supplementary Fig. S1) resulted in near-complete loss of APOAI expression in BAEC under static conditions (>99%; P=0.002; Fig. 1a). Because this sequence seemed essential to the activity of the 4XETE promoter/enhancer even under static conditions, we left it intact in vectors designed to test whether addition of an exogenous SSRE could increase shear-responsive expression from the 4XETE-gApoAI-oPRE cassette.

We next transfected BAEC with plasmids containing the 4XETE-gApoAI-oPRE and SSRE-4XETE-gApoAI-oPRE expression cassettes (Supplementary Fig. S1). The latter plasmid has an exogenous SSRE (5´-GAGACC-3´)(28) placed upstream of the 4XETE sequence but is otherwise identical to the plasmid containing 4XETE-gApoAI-oPRE. Addition of the SSRE had no effect on APOAI expression in BAEC maintained under static conditions (Fig. 1b; P=0.4). To test if this SSRE increases APOAI expression in response to fluid shear stress in vivo, we transferred the SSRE-4XETE-gApoAI-oPRE expression cassette into an HDAd vector and compared it to HDAd-4XETE-gApoAI-oPRE in vivo in rabbit carotid arteries, using a model of EC-specific in vivo gene transfer.(51, 53) Addition of the SSRE to 4XETE-gApoAI-oPRE did not alter APOAI expression (Fig. 1c; P=0.8 and 0.5 at 3 and 28 days, respectively).

Addition of a Mef2c enhancer element increases expression from a moderately active promoter/enhancer but not from a highly active promoter/enhancer

We next tested the activity of a 44-bp enhancer element in the mouse Mef2c locus. When placed upstream of a heterologous promoter, this sequence is sufficient to direct vascular EC-specific expression in zebrafish embryos.(32) This Mef2c enhancer is highly evolutionarily conserved, and is bound/activated by Fox and Ets transcription factors. Similar FOX:ETS motifs are present in several EC-specific enhancers,(32) suggesting that placement of Mef2c enhancer copies upstream of the 4XETE promoter/enhancer could recruit EC-expressed transcription factors and increase APOAI expression. We tested whether addition of this Mef2c enhancer could increase expression from our highest-expressing cassette (4XETE-gApoAI-oPRE),(23) by inserting 1–5 copies of the Mef2c enhancer upstream of the 4XETE promoter/enhancer in pBshuttle-4XETE-gApoAI-oPRE (Supplementary Fig. S1). Transfection of these constructs into BAEC (Fig. 2a) showed that addition of Mef2c enhancers either decreased APOAI expression (1, 2, 3 and 5 enhancer copies; P<0.01 for all) or had no significant effect (4 copies; P=0.6).

We considered that competition for transcription-factor binding between the Mef2c enhancer and the 4 Edn1 enhancers in 4XETE might account for failure of the Mef2c enhancer to increase APOAI expression above levels obtained with 4XETE-gApoAI-oPRE. We also considered a related observation: that some enhancers activate transcription more potently when they are adjacent to a moderately active promoter than when they are adjacent to a highly active promoter.(24) Accordingly, we inserted 1–5 copies of the Mef2c enhancer upstream of the moderately active 1XETE promoter (in pBshuttle-1XETE-gApoAI-oPRE; Supplementary Fig. S1) and transfected BAEC with these constructs. A construct that included 2 copies of the Mef2c enhancer upstream of 1XETE-gApoAI-oPRE (2XMEF2C-1XETE-gApoAI-oPRE) significantly increased APOAI expression, compared to the 1XETE-gApoAI-oPRE cassette (5.6-fold; P<0.05; Fig. 2b). In contrast, APOAI expression from constructs containing 1, 3, 4, or 5 copies of the Mef2c enhancer did not differ significantly from the 1XETE-gApoAI-oPRE cassette. APOAI expression from the 4XETE-gApoAI-oPRE construct (included as a positive control) was higher than from 2XMEF2C-1XETE-gApoAI-oPRE (16-fold above 1XETE-gApoAI-oPRE; P<0.001; Fig. 2b).

Identification of EC-specific CRM and testing in BAEC, HAEC, and HUVEC

We next tested a bioinformatics-based approach, shown previously to be useful in generating high-expressing cell-type-specific expression cassettes for hepatocytes, cardiomyocytes, and skeletal myocytes.(24-26) This approach exploits short DNA sequences (cis-regulatory modules; CRM), identified as transcriptionally active based on their ability to bind transcription factors near promoters of genes that are highly expressed in specific cell types (Fig. 3). To identify EC-specific CRM, we first identified 8 transcription-factor binding sites (TFBS) that: (i) are preferentially associated with 4 highly expressed relatively EC-specific genes (CDH5, EFEMP1, THBS1, VWF; (https://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-26284/);(34) and (ii) tend to co-occur in proximity to each other within evolutionarily conserved regions that are transcriptionally active in HUVEC (based on presence of open chromatin and histone marks of active transcription). These TFBS contain consensus binding-sites for the transcription factors AR, E2F7, ESR2, ETS1, GATA3, PRDM1, SNAPC1, and TAF7. By scanning within 2 kb of the transcription start sites of the 4 highly expressed relatively EC-specific genes, we identified 11 DNA segments that include clusters of these TFBS and might therefore represent EC-specific CRM. These 11 CRM (55–352 bp) are located in the promoters or introns of the 4 relatively EC-specific genes: CDH5 (CRM 1-4), EFEMP1 (CRM 5-7), THBS1 (CRM 8-10), and VWF (CRM11) (Supplementary Fig. S2).

We cloned each of the 11 CRM from human DNA and inserted them into both pBshuttle-1XETE-gApoAI-oPRE and pBshuttle-4XETE-gApoAI-oPRE, just upstream of the 1XETE and 4XETE promoter/enhancer sequences (Supplementary Fig. S1). Transfection of the 1XETE-based CRM-containing constructs into BAEC revealed that CRM2 and CRM10 significantly increased APOAI expression from 1XETE-gApoAI-oPRE (2-fold; P=0.02 for CRM2 and 7-fold P<0.001 for CRM10; Fig. 4a). In comparison, BAEC transfected in parallel with pBshuttle-4XETE-gApoAI-oPRE (without an added CRM) expressed 10-fold more APOAI mRNA than pBshuttle-1XETE-gApoAI-oPRE (P<0.001). Transfection of the 4XETE-based CRM-containing constructs into BAEC revealed that none of the 11 CRM significantly increased APOAI expression from 4XETE-gApoAI-oPRE (Fig. 4b).

Because we cloned the CRM from human DNA, we considered that they might more-effectively bind transcription factors and increase APOAI expression in human rather than bovine cells. For this reason, we next tested the CRM in human aortic endothelial cells (HAEC). Because of technical challenges in expanding large numbers of HAEC, we began by screening all 11 CRM in 2 independent transfections. Based on these results (Fig. 4c and 4d), we selected CRM 2 and 10 for further testing with the 1XETE-gApoAI-oPRE backbone and CRM 3 and 6 for further testing with the 4XETE-gApoAI-oPRE backbone. In a larger series of transfections, however, none of these 4 CRM significantly altered expression from the corresponding backbones (Fig. 5a and 5b).

We next considered that the CRM were identified based on gene-expression data from cultured HUVEC (see Methods). Accordingly, we screened all 11 CRM in HUVEC, again with 2 separate transfections. Based on these results (Fig. 4e and 4f), we selected CRM 2 and 3 for further testing with the 1XETE-gApoAI-oPRE backbone and CRM 3 and 11 for further testing with the 4XETE-gApoAI-oPRE backbone. In a larger series of transfections, both CRM2 and CRM3 significantly increased expression from 1XETE-gApoAI-oPRE (2.1-fold; P<0.01 and 2.3-fold; P<0.001, respectively; Fig. 5c). Neither CRM3 nor CRM11 significantly altered expression from 4XETE-gApoAI-oPRE (Fig. 5d).

Insertion of the APOAI gene at the transcription start site of highly expressed EC genes

We noted that CRM 2, 3, and 10 could increase APOAI expression from the 1XETE-gApoAI-oPRE backbone (Fig. 4a and Fig. 5c) but not from the 4XETE-gApoAI-oPRE backbone (in which the DNA sequences adjacent to the CRM and the distance from the CRM to the transcription start site differ). Moreover, all CRM were identified based on attributes (e.g., presence of open chromatin, transcription factor binding activity) that were measured in their native genomic contexts. Accordingly, we hypothesized that the CRM might function more optimally in their genomic contexts (i.e., when they are situated among native neighboring DNA sequence and are separated from nearby transcription start sites by the same number of nucleotides as in the human genome). To test this hypothesis, we cloned the CRM-containing genomic regions of CDH5, EFEMP1, THBS1, and VWF and inserted the rabbit APOAI gene into the translation start site of each of these 4 genes (Supplementary Fig. S2).

When transfected into BAEC (Fig. 6a), the CDH5-based cassette expressed APOAI at a similar level to the 1XETE-gApoAI-oPRE construct (which is essentially a “knock-in” of the rabbit APOAI gene to a segment of the mouse Edn1 locus, with the oPRE added; Supplementary Fig. S1). The EFEMP1 and VWF-based cassettes expressed APOAI at a lower level than 1XETE-gApoAI-oPRE (92% less; P=0.002 and 80% less; P=0.09, respectively); whereas, the THBS1-based cassette expressed at a nominally higher level (3-fold; P=0.3). To determine whether the THBS1 result was falsely negative due to low statistical power associated with multiple comparisons, we performed new transfections that compared 1XETE-gApoAI-oPRE to THBS1-gApoAI-oPRE. We again found no significant difference in APOAI expression (P=0.6; Supplemental Fig. S3).

Finally, for reasons described above, we tested the 4 knock-in cassettes in human EC: HAEC and HUVEC. We included an empty vector control (pBshuttle), to measure the absolute performance of all cassettes in these cell types. We included the 4XETE-gApoAI-oPRE cassette to compare the 4 new cassettes to our highest-expressing cassette.(22, 23) When transfected into HAEC (Fig. 6b), all 4 of the new cassettes expressed APOAI at levels higher than the background signal in the vector-only control group (from ~6-fold for EFEMP1 to ~180-fold for CDH5). However, none of the 4 cassettes expressed more APOAI mRNA than 1XETE-gApoAI-oPRE, with median expression ranging from ~3% (EFEMP1) to ~80% (CDH5) of 1XETE-gApoAI-oPRE levels. The EFEMP1 and VWF-based cassettes expressed apoAI at a significantly lower level than 1XETE-gApoAI-oPRE (97% less; P<0.0001; and 91% less; P<0.01, respectively). In contrast, 4XETE-gApoAI-oPRE expressed apoAI at ~30-fold higher levels than 1XETE-gApoAI-oPRE.

When transfected into HUVEC (Fig. 6c), all 4 knock-in cassettes expressed APOAI far above the signal in the vector-only control group (from ~65-fold for EFEMP1 to ~6,000-fold for CDH5). Expression from the CDH5-based cassette was essentially identical to expression from 1XETE-gApoAI-oPRE; the other 3 cassettes expressed at far lower levels (1%–13% of 1XETE-gApoAI-oPRE levels). Again, 4XETE-gApoAI-oPRE expressed higher levels of APOAI mRNA than 1XETE-gApoAI-oPRE (~6-fold; P<0.005).

We tested several strategies aimed at increasing expression of a rabbit APOAI transgene in vascular endothelial cells. Our major findings are: (1) addition of an SSRE sequence to our previously highest-expressing expression cassette (4XETE-gAPOAI-oPRE) did not increase transgene expression in EC in vitro or in vivo. (2) Addition of 2 Mef2c enhancer elements significantly increased EC transgene expression from a moderately active expression cassette (1XETE-gAPOAI-oPRE) but not from 4XETE-gAPOAI-oPRE. (3) Similarly, we identified 3 CRM (of 11 potential EC-specific CRM) that increased EC transgene expression from 1XETE-gAPOAI-oPRE); however, none of the 11 CRM increased transgene expression from 4XETE-gAPOAI-oPRE. (4) Insertion of the rabbit APOAI gene into the transcription start sites of 4 highly expressed EC genes did not increase APOAI expression above 1XETE-gAPOAI-oPRE.

Houston et al reported that an SSRE (GAGACC)—first identified in the platelet-derived growth factor promoter and conserved in several shear-stress-responsive genes—increased transgene expression from a heterologous promoter in response to shear stress both in vitro (3–8-fold) and in vivo (10-fold, in rabbit carotid arteries).(28) This SSRE binds specifically to nuclear extracts of both static and shear-stressed EC, although the binding proteins were not identified.(27) Presumably, these binding proteins include transcription factors or co-regulators that are activated by shear, prompting us to add the SSRE to the 4XETE promoter/enhancer. Failure of the SSRE to increase APOAI transgene expression in shear stress-exposed EC in vivo might be explained by generation of binding site(s) for transcriptional repressors in the SSRE-4XETE construct, lack of synergy with factors bound to 4XETE, competition by the endogenous GAGACC sequence in 4XETE, or insufficient shear stress in our transduced carotid arteries.

Others have used EC-specific enhancers (e.g., from NOS3 and TEK) to increase EC-specific transgene expression from heterologous promoters.(54, 55) De Val et al identified a highly conserved 44-bp enhancer sequence in the mouse Mef2c locus that was sufficient to drive EC-specific gene expression in vivo. Moreover, when placed upstream of a heterologous promoter and transfected in vitro, expression driven by this 44-bp sequence was upregulated 40-fold by co-transfection of the Foxc2 and Etv2 transcription factors.(32) This 44-bp sequence contains a FOX:ETS motif that is overrepresented in EC-expressed genes, increasing the likelihood that it would be active in multiple genomic contexts, including ours. Moreover, because EC enhancer activity can be increased by concatemerization,(22, 56) we inserted 1–5 Mef2c enhancer copies upstream of our promoters. Addition of 2 copies of the 44-bp enhancer significantly increased expression from 1XETE; however, all the Mef2c enhancer constructs substantially decreased expression when placed upstream of 4XETE. Potential explanations include competition for transcription factor binding between the Mef2c enhancers and the 4 Edn1-derived enhancers in 4XETE or direct interactions between the ETE and Mef2c enhancers that interfere with transcription factor binding.

Cell type-specific CRM were initially identified by measuring highly expressed and lowly expressed genes in organ total-RNA extracts, then scanning promoter regions to identify—in the highly expressed genes—short DNA sequences containing TFBS that are over-represented and co-occur.(24–26) This approach identified CRM that—when fused to heterologous tissue-specific promoters—significantly increased in vivo transgene expression in liver, cardiomyocytes, and skeletal muscle. The activity of the CRM in these initial reports was impressive, increasing in vivo transgene expression from plasmids and AAV vectors by up to 200–400-fold and preserving tissue specificity.(24–26) However, this early work on CRM-containing vectors from the Chuah/VandenDriessche group and others(57–63) also revealed limitations: (1) Some of the initially described CRM had no effect or decreased expression when placed upstream of the transthyretin promoter.(24) (2) CRM activity depends both on the identity of the adjacent promoter and on the transgene that is expressed, with up to 10-fold differences in CRM activity depending on the promoter,(24–26, 58) and similar transgene-dependent variability.(26) (3) Several reports that used CRM did not compare CRM-containing vectors to vectors that differed only in lacking the CRM.(58–60, 62) In one case, this comparison revealed that addition of a cardiomyocyte-specific CRM to the cardiac troponin T promoter either had no effect or decreased transgene expression in mouse hearts.(61) (4) When compared to enhancer-promoter combinations that lack identified CRMs, CRM-containing vectors have not always yielded the highest levels of expression.(60)

In the present study, we identified 3 EC-specific CRM (2, 3, and 10) that increased transgene expression from the 1XETE expression cassette. The most impressive results were obtained with CRM10 in BAEC (7-fold increase), yielding levels almost as high as the 4XETE cassette. However, CRM10 did not reliably increase transgene expression from the 1XETE cassette in the 2 other EC types and none of the CRM increased transgene expression from the 4XETE cassette. We considered several reasons for these results. First, in HAEC and HUVEC we performed 2 screening transfections of the 11 CRM, then focused on only 2 CRM. Additional transfections might have revealed high activity of the CRM that were screened out at the first step. However, this seems unlikely because when CRM boosted expression, they did so consistently (Figs. 4a and 5c). Second, we screened promoters of only 4 highly and lowly expressed genes, whereas other studies screened promoters of 29–59 highly expressed genes.(24–26) However, the optimal number of input genes for this approach is uncertain, and use of a larger number of genes in the ENCODE data set (Supplementary Table 1) to identify EC-specific CRM could risk obscuring signal with noise.(26) Third, we might have used suboptimal EC types to screen for CRM activity. We attempted to address this by including HUVEC, the same cell type in which the highly expressed genes were identified (see Methods). However, it is possible that differences in cell origin or culture conditions(64) created a mismatch between the cellular transcriptional environment in which the CRM were discovered and the environment in which we tested the CRM. Fourth, the abundance of a transcription factor that binds to 4XETE may be limiting, blocking activity of added CRM.

In contrast to our in vitro-based approach, CRM active in hepatocytes, cardiomyocytes, and skeletal muscle were all identified using in vivo transcriptomes of whole liver, heart, and muscle. (24–26) A potential limitation of the in vivo approach is that transcripts in whole organ extracts could originate from any of several cell types. Because EC are a minority cell type in all organs, we decided at the outset of this project to use in vitro data (from purified EC) to identify highly expressed EC genes. Recent single-cell RNA sequencing data now provides access to the in vivo EC transcriptome.(65, 66) Future efforts to identify EC-specific CRM should leverage these newly available data rather than relying, as we did, on data from cultured cells.

Insertion of a transgene into a locus with high cell-specific transcriptional activity is an effective means for achieving high levels of tissue-specific transgene expression.(67) Both the 1XETE and 4XETE cassettes are based on this premise because transgenes inserted into the Edn1 locus (elements of which are included in 1XETE and 4XETE) are expressed at high levels in EC in vivo.(68) We attempted to generate cassettes with higher APOAI transgene expression than 4XETE by inserting the APOAI gene into vectors that contain core transcriptional elements of 4 other highly expressed EC genes. All vectors expressed APOAI mRNA far above background (up to 6 000-fold for the CDH5-derived cassette in HUVEC; equivalent to 1XETE); however, none of the vectors expressed APOAI mRNA at a higher level than 1XETE and all expressed far less APOAI mRNA than 4XETE. We speculate that the high activity of 4XETE (which outperforms the CMV promoter in HUVEC)(23) might be explained by addition of engineered enhancer elements (3 Edn1 enhancers) to the endogenous Edn1 sequence.

In conclusion, we identified several sequences that are transcriptionally active in cultured EC. However, none of these sequences yielded an expression cassette with higher activity than 4XETE. Future strategies might include techniques such as Hi-C(69) to identify distant sequences that transactivate highly expressed EC-specific genes, use of in vivo EC transcriptome data to identify other highly expressed EC genes and their CRM (with incorporation of these new CRM into expression cassettes), and insertion of transgenes into the loci of these newly identified EC genes.

Acknowledgments We thank Richard Palmiter and Stephen Hauschka for helpful discussions. We thank AdVec, Inc. for permission to use the HDAd reagents.

Author contributions M.S., N.G., L.B., B.K.W., and E.K. acquired data and contributed to the design of the work. P.D.B. acquired data and helped conceive and design the work. D.A.D. contributed to conception and design of the work. All authors interpreted results and contributed to writing and reviewing the manuscript.

Funding This study was supported by a grant from the National Institutes of Health (R01HL114541; D.A.D.) and by scholarships from the University of Washington (M.S. and E.K.).

Data availability statement The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Compliance with ethical standards All animal studies were approved by the Office of Animal Welfare of the University of Washington.

Conflict of interest None of the authors have a conflict of interest directly related to the content of the manuscript.

De Caterina R, Libby P, editors. Endothelial Dysfunctions and Vascular Disease. Malden, MA: Blackwell; 2007.
Zwiebel JA, Freeman SM, Kantoff PW, Cornetta K, Ryan US, Anderson WF. High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. Science. 1989;243:220–2.
Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342–4.
Vandendriessche T, Chuah MK. Targeting endothelial cells by gene therapy. Blood. 2013;122:1993–4.
Gimbrone MA, Jr., Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–36.
Huang L, Chambliss KL, Gao X, Yuhanna IS, Behling-Kelly E, Bergaya S, et al. SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature. 2019;569:565–9.
Remes A, Basha DI, Frey N, Wagner AH, Muller OJ. Gene transfer to the vascular system: Novel translational perspectives for vascular diseases. Biochem Pharmacol. 2020;182:114265.
Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity. Circulation. 1995;91:2407–14.
Flotte TRE-i-C. Revisiting the "New" Inflammatory Toxicities of Adeno-Associated Virus Vectors. Hum Gene Ther. 2020;31:398–9.
Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 2000;7:896–902.
Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol. 2001;19:838–42.
Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension. 2001;38:65–70.
Velasco B, Ramirez JR, Relloso M, Li C, Kumar S, Lopez-Bote JP, et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther. 2001;8:897–904.
De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther. 2003;14:1193–206.
Richardson TB, Kaspers J, Porter CD. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Ther. 2004;11:775–83.
White SJ, Papadakis ED, Rogers CA, Johnson JL, Biessen EA, Newby AC. In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer. Gene Ther. 2008:340–6.
Giacalone JC, Miller MJ, Workalemahu G, Reutzel AJ, Ochoa D, Whitmore SS, et al. Generation of an immortalized human choroid endothelial cell line (iChEC-1) using an endothelial cell specific promoter. Microvasc Res. 2019;123:50–7.
Sun S, Qin W, Tang X, Meng Y, Hu W, Zhang S, et al. Vascular endothelium-targeted Sirt7 gene therapy rejuvenates blood vessels and extends life span in a Hutchinson-Gilford progeria model. Sci Adv. 2020;6:eaay5556.
Wacker BK, Dronadula N, Bi L, Stamatikos A, Dichek DA. Apolipoprotein A-I vascular gene therapy provides durable protection from atherosclerosis in hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2018;38:206–17.
Wacker BK, Dronadula N, Zhang J, Dichek DA. Local vascular gene therapy with apolipoprotein A-I to promote regression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37:316–27.
Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73:2886–92.
Dronadula N, Du L, Flynn R, Buckler JM, Kho J, Jiang Z, et al. Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels. Gene Ther. 2011;18:501–8.
Dronadula N, Wacker BK, Van Der Kwast R, Zhang J, Dichek DA. Stable in vivo transgene expression in endothelial cells with helper-dependent adenovirus: roles of promoter and interleukin-10. Hum Gene Ther. 2017;28:255–70.
Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, et al. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther. 2014;22:1605–13.
Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts M, Matrai J, Samara-Kuko E, et al. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy. Mol Ther. 2015;23:43–52.
Sarcar S, Tulalamba W, Rincon MY, Tipanee J, Pham HQ, Evens H, et al. Next-generation muscle-directed gene therapy by in silico vector design. Nat Commun. 2019;10:492.
Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF, Jr., Gimbrone MA, Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A. 1993;90:4591–5.
Houston P, White BP, Campbell CJ, Braddock M. Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. Hum Gene Ther. 1999;10:3031–44.
Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996;93:13565–70.
Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet. 1996;22:477–88.
Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498–509.
De Val S, Chi NC, Meadows SM, Minovitsky S, Anderson JP, Harris IS, et al. Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors. Cell. 2008;135:1053–64.
Blachinsky E, Marbach I, Cohen R, Grably MR, Engelberg D. Procedure for controlling number of repeats, orientation, and order during cloning of oligonucleotides. Biotechniques. 2004;36:933–6.
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.
Blancafort P, Magnenat L, Barbas CF, 3rd. Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol. 2003;21:269–74.
Blackburn J, Tarttelin EE, Gregory-Evans CY, Moosajee M, Gregory-Evans K. Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci. 2003;44:4613–21.
Chandler RL, Brennan J, Schisler JC, Serber D, Patterson C, Magnuson T. ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol Cell Biol. 2013;33:265–80.
Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003;63:6299–310.
Sahu S, Ganguly R, Raman P. Leptin augments recruitment of IRF-1 and CREB to thrombospondin-1 gene promoter in vascular smooth muscle cells in vitro. Am J Physiol Cell Physiol. 2016;311:C212–24.
Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, et al. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood. 2010;116:3645–52.
Liu J, Yuan L, Molema G, Regan E, Janes L, Beeler D, et al. Vascular bed-specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle. Blood. 2011;117:342–51.
Guan J, Guillot PV, Aird WC. Characterization of the mouse von Willebrand factor promoter. Blood. 1999;94:3405–12.
Bonthron D, Orkin SH. The human von Willebrand factor gene. Structure of the 5' region. Eur J Biochem. 1988;171:51–7.
Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol. 1994;14:999–1008.
GuhaThakurta D. Computational identification of transcriptional regulatory elements in DNA sequence. Nucleic Acids Res. 2006;34:3585–98.
Griffon A, Barbier Q, Dalino J, van Helden J, Spicuglia S, Ballester B. Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res. 2015;43:e27.
Wang J, Zhuang J, Iyer S, Lin XY, Greven MC, Kim BH, et al. Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium. Nucleic Acids Res. 2013;41(Database issue):D171-6.
Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 2011;71:6940–7.
De Bleser P, Hooghe B, Vlieghe D, van Roy F. A distance difference matrix approach to identifying transcription factors that regulate differential gene expression. Genome Biol. 2007;8:R83.
Heskes T, Eisinga R, Breitling R. A fast algorithm for determining bounds and accurate approximate p-values of the rank product statistic for replicate experiments. BMC Bioinformatics. 2014;15:367.
Wacker BK, Bi L, Dichek DA. In vivo gene transfer to the rabbit common carotid artery endothelium. J Vis Exp. 2018;135:56982.
Flynn R, Qian K, Tang C, Dronadula N, Buckler J, Jiang B, et al. Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis. Mol Ther. 2011;19:1833–41.
Jiang B, Qian K, Du L, Luttrell I, Chitaley K, Dichek DA. Helper-dependent adenovirus is superior to first-generation adenovirus for expressing transgenes in atherosclerosis-prone arteries. Arterioscler Thromb Vasc Biol. 2011;31:1317–25.
Laumonnier Y, Nadaud S, Agrapart M, Soubrier F. Characterization of an upstream enhancer region in the promoter of the human endothelial nitric-oxide synthase gene. J Biol Chem. 2000;275:40732–41.
Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, Deutsch U, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997;94(7):3058–63.
Bu X, Quertermous T. Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J Biol Chem. 1997;272:32613–22.
Nair N, Rincon MY, Evens H, Sarcar S, Dastidar S, Samara-Kuko E, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood. 2014;123:3195–9.
Brown HC, Doering CB, Herzog RW, Ling C, Markusic DM, Spencer HT, et al. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Hum Gene Ther. 2020;31:1114–23.
Singh K, Evens H, Nair N, Rincon MY, Sarcar S, Samara-Kuko E, et al. Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9. Mol Ther. 2018;26:1241–54.
Ahmed SS, Rubin H, Wang M, Faulkner D, Sengooba A, Dollive SN, et al. Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH. Mol Ther Methods Clin Dev. 2020;17:568–80.
Chamberlain K, Riyad JM, Garnett T, Kohlbrenner E, Mookerjee A, Elmastour F, et al. A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. Hum Gene Ther. 2018;29(8):927–37.
Ghaderi S, Alidadiani N, Soleimani Rad J, Heidari HR, Dilaver N, Mansoori B, et al. Construction and Development of a Cardiac Tissue-Specific and Hypoxia-Inducible Expression Vector. Adv Pharm Bull. 2018;8:29–38.
Yoo J, Kohlbrenner E, Kim O, Hajjar RJ, Jeong D. Enhancing atrial-specific gene expression using a calsequestrin cis-regulatory module 4 with a sarcolipin promoter. J Gene Med. 2018;20:e3060.
Dichek D, Quertermous T. Variability in messenger RNA levels in human umbilical vein endothelial cells of different lineage and time in culture. In Vitro Cell Dev Biol. 1989;25:289–92.
Tabula Muris C, Overall c, Logistical c, Organ c, processing, Library p, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature. 2018;562(7727):367 – 72.
Kalluri AS, Vellarikkal SK, Edelman ER, Nguyen L, Subramanian A, Ellinor PT, et al. Single-Cell Analysis of the Normal Mouse Aorta Reveals Functionally Distinct Endothelial Cell Populations. Circulation. 2019;140:147–63.
Barzel A, Paulk NK, Shi Y, Huang Y, Chu K, Zhang F, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015;517(7534):360–4.
Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest. 1995;95:1335–44.
Jerkovic I, Cavalli G. Understanding 3D genome organization by multidisciplinary methods. Nat Rev Mol Cell Biol. 2021;22:511–28.

There is NO conflict of interest to disclose.

SethramanetalSupplementaryInformation.pdf

Download PDF

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Novel expression cassettes for increasing apolipoprotein AI transgene expression in vascular endothelial cells

Archived Versions:

Version 1

Abstract

Figures

Introduction

Materials And Methods

Results

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Archived Versions:

Version 1